Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.46 |
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | MMP1 | P03956 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
| ▸ | MMP12 | P39900 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6994441 | 0.86 | MAPT (0.60) | MAPTKDM4ECYP1A2CYP2D6CYP2C9 | |
| SCHEMBL6841138 | 0.84 | CA12 (0.47) | MAPTKDM4ECYP1A2CYP2D6CYP2C9 | |
| SCHEMBL6998468 | 0.82 | MAPT (0.46) | MAPTKDM4ECYP1A2CYP2D6CYP2C9 | |
| SCHEMBL5335214 | 0.76 | MAPT (0.63) | MAPTKDM4ECYP1A2CYP2D6CYP2C9 | |
| SCHEMBL6836839 | 0.73 | ESR1 (0.57) | MAPTLMNASMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL4428377 | 0.72 | MAPT (0.55) | MAPTKMT2AMEN1LMNAMMP1 | |
| SCHEMBL31538461 | 0.72 | KMT2A (0.61) | MAPTKDM4ECYP1A2KMT2AMEN1 | |
| SCHEMBL7221633 | 0.72 | PPARG (0.45) | MAPTKDM4ECYP1A2CYP2D6CYP2C9 | |
| SCHEMBL663552 | 0.71 | KMT2A (0.76) | MAPTKDM4EKMT2AMEN1LMNA | |
| SCHEMBL6836982 | 0.71 | ESR1 (0.48) | MAPTKDM4EKMT2ALMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063785-A1 | Symmetrically disubstituted aromatic compounds and pharmaceutical compositions for inhibiting poly (ADP-ribose) glycohydrolase, and methods for their use | GUILFORD PHARMACEUTICALS, INC. | 2004-04-01 | — | — | US | disclosed |
| US-6635786-B2 | Symmetrically disubstituted aromatic compounds and pharmaceutical compositions for inhibiting poly (ADP-ribose) glycohydrolase, and methods for their use | GUILFORD PHARMACEUTICALS, INC. | 2003-10-21 | — | — | US | disclosed |
| US-20020132852-A1 | Symmetrically disubstituted aromatic compounds and pharmaceutical compositions for inhibiting poly (ADP-ribose) glycohydrolase, and methods for their use | GUILFORD PHARMACEUTICALS, INC. | 2002-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063785-A1 | Symmetrically disubstituted aromatic compounds and pharmaceutical compositions for inhibiting poly (ADP-ribose) glycohydrolase, and methods for their use | PARG, PARP1, PARP11 | MAPT 1519/4885KDM4E 1769/4885CYP1A2 2018/4885 |
| US-20020132852-A1 | Symmetrically disubstituted aromatic compounds and pharmaceutical compositions for inhibiting poly (ADP-ribose) glycohydrolase, and methods for their use | PARG, PARP1, PARP11 | MAPT 1519/4885KDM4E 1769/4885CYP1A2 2018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.